OBJECTIVE: in HIV populations that are aging due to improved longevity with combination antiretroviral therapy (CART), both hypertriglyceridemia (hTRG) and sensory neuropathy have become increasingly common. Sensory neuropathy is associated with substantial long-term disability and frequently requires management with analgesics. Elevated serum triglycerides (TRGs) are associated with an increased risk for sensory neuropathy in diabetes mellitus. However, the contribution of hTRG to sensory neuropathy in HIV has not been carefully evaluated. DESIGN: prospective, comparative, single-center, cross-sectional cohort study. METHODS: clinical correlates of sensory neuropathy were assessed in HIV-positive and HIV-negative participants. HIV-sensory neuropathy was defined as one or more clinical signs of reduced distal sensation or ankle reflexes; symptoms were distal leg and foot pain, parasthesias or numbness. TRG levels were assessed along with concomitant metabolic and other risk factors including glucose, lipids, age, height, current and nadir CD4, and past or current use of protease inhibitors, dideoxynucleoside antiretrovirals (d-drugs), and statins in univariable and multivariable logistic regression. RESULTS: of 436 HIV patients (median age 52 years; 75% on CART), 27% had sensory neuropathy; 48% were symptomatic. TRG levels were significantly higher in HIV-positive than HIV-negative individuals (mean ± SD, 245 ± 242 versus 160 ± 97 mg/dl; P < 0.001). Among HIV-positive patients, those with TRG levels in the highest tertile (≥ 244 mg/dl) were more likely to have sensory neuropathy than those in the lowest tertile (reference, ≤ 142 mg/dl) after adjusting for concurrent predictors (adjusted odds ratio 2.7, 95% confidence interval 1.4-5.5). CONCLUSIONS: elevated triglyceride levels increased the risk for HIV-sensory neuropathy in HIV-positive individuals independently of other known risk factors. 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
OBJECTIVE: in HIV populations that are aging due to improved longevity with combination antiretroviral therapy (CART), both hypertriglyceridemia (hTRG) and sensory neuropathy have become increasingly common. Sensory neuropathy is associated with substantial long-term disability and frequently requires management with analgesics. Elevated serum triglycerides (TRGs) are associated with an increased risk for sensory neuropathy in diabetes mellitus. However, the contribution of hTRG to sensory neuropathy in HIV has not been carefully evaluated. DESIGN: prospective, comparative, single-center, cross-sectional cohort study. METHODS: clinical correlates of sensory neuropathy were assessed in HIV-positive and HIV-negative participants. HIV-sensory neuropathy was defined as one or more clinical signs of reduced distal sensation or ankle reflexes; symptoms were distal leg and foot pain, parasthesias or numbness. TRG levels were assessed along with concomitant metabolic and other risk factors including glucose, lipids, age, height, current and nadir CD4, and past or current use of protease inhibitors, dideoxynucleoside antiretrovirals (d-drugs), and statins in univariable and multivariable logistic regression. RESULTS: of 436 HIV patients (median age 52 years; 75% on CART), 27% had sensory neuropathy; 48% were symptomatic. TRG levels were significantly higher in HIV-positive than HIV-negative individuals (mean ± SD, 245 ± 242 versus 160 ± 97 mg/dl; P < 0.001). Among HIV-positive patients, those with TRG levels in the highest tertile (≥ 244 mg/dl) were more likely to have sensory neuropathy than those in the lowest tertile (reference, ≤ 142 mg/dl) after adjusting for concurrent predictors (adjusted odds ratio 2.7, 95% confidence interval 1.4-5.5). CONCLUSIONS: elevated triglyceride levels increased the risk for HIV-sensory neuropathy in HIV-positive individuals independently of other known risk factors. 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Authors: Andrea M Vincent; John M Hayes; Lisa L McLean; Anuradha Vivekanandan-Giri; Subramaniam Pennathur; Eva L Feldman Journal: Diabetes Date: 2009-07-10 Impact factor: 9.461
Authors: C L Cherry; J S Affandi; D Imran; E Yunihastuti; K Smyth; S Vanar; A Kamarulzaman; P Price Journal: Neurology Date: 2009-07-28 Impact factor: 9.910
Authors: Beau M Ances; Florin Vaida; Debralee Rosario; Jennifer Marquie-Beck; Ronald J Ellis; David M Simpson; David B Clifford; Justin C McArthur; Igor Grant; J Allen McCutchan Journal: AIDS Date: 2009-11-13 Impact factor: 4.177
Authors: Ronald J Ellis; Jennifer Marquie-Beck; Patrick Delaney; Terry Alexander; David B Clifford; Justin C McArthur; David M Simpson; Christopher Ake; Ann C Collier; Benjamin B Gelman; J Allen McCutchan; Susan Morgello; Igor Grant Journal: Ann Neurol Date: 2008-11 Impact factor: 10.422
Authors: Timothy D Wiggin; Kelli A Sullivan; Rodica Pop-Busui; Antonino Amato; Anders A F Sima; Eva L Feldman Journal: Diabetes Date: 2009-05-01 Impact factor: 9.461
Authors: Scott R Evans; Ronald J Ellis; Huichao Chen; Tzu-min Yeh; Anthony J Lee; Giovanni Schifitto; Kunling Wu; Ronald J Bosch; Justin C McArthur; David M Simpson; David B Clifford Journal: AIDS Date: 2011-04-24 Impact factor: 4.177
Authors: Huichao Chen; David B Clifford; Lijuan Deng; Kunling Wu; Anthony J Lee; Ronald J Bosch; Sharon A Riddler; Ronald J Ellis; Scott R Evans Journal: J Neurovirol Date: 2013-12-03 Impact factor: 2.643
Authors: Jemily Malvar; Florin Vaida; Chelsea Fitzsimons Sanders; J Hampton Atkinson; William Bohannon; John Keltner; Jessica Robinson-Papp; David M Simpson; Christina M Marra; David B Clifford; Benjamin Gelman; Juanjuan Fan; Igor Grant; Ronald J Ellis Journal: Pain Date: 2015-04 Impact factor: 7.926
Authors: Frank Ndaks Ndakala; Julius Otieno Oyugi; Margaret Ng'wono Oluka; Joshua Kimani; Alexandra Jablonka; Georg Martin Norbert Behrens Journal: Pan Afr Med J Date: 2016-09-20
Authors: Whitney Scott; Chinar Arkuter; Kitty Kioskli; Harriet Kemp; Lance M McCracken; Andrew S C Rice; Amanda C de C Williams Journal: Pain Date: 2018-12 Impact factor: 6.961